Avanos Medical Inc (AVNS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Avanos Medical Inc (AVNS) has an earnings forecast score of 6.00, placing it 174th in the Healthcare Equipment & Supplies industry. Analysts have set a target price of $14.00 for AVNS, with one analyst recommending a "Hold" rating. The company's expected revenue for the next quarter is $173.00M, and its previous quarter's EPS was -$0.03 against an expectation of $0.11, with the next quarter's EPS expected at $0.16.
FNY Investment Advisers LLC Purchases New Stake in Avanos Medical, Inc. $AVNS
FNY Investment Advisers LLC has acquired a new stake in Avanos Medical, Inc. (NYSE:AVNS), purchasing 103,500 shares valued at approximately $2.575 million, which now represents 0.9% of FNY’s holdings and 0.22% of Avanos Medical. Other institutional investors have also adjusted their positions in AVNS. Despite the stock opening near its 52-week high, analyst sentiment remains cautious with a consensus "Reduce" rating, although the company recently beat earnings expectations.
AVANOS MEDICAL, INC. SEC Filing (Aug 6, 2026)
AVANOS MEDICAL, INC. (AVNS) filed a Form 15 with the SEC on August 6, 2026, certifying the termination of its registration under Section 12(g) and suspension of its duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. This filing indicates that the company is no longer required to submit regular reports to the SEC. The action follows recent events including the completion of its acquisition by American Industrial Partners and stockholder approval of the merger.
Enterprise value to EBITDA forward of Avanos Medical, Inc. – SWB:8HH
The article focuses on the "Enterprise value to EBITDA forward" metric for Avanos Medical, Inc. (SWB:8HH) listed on the Stuttgart Stock Exchange. The content is primarily a navigation-heavy page from TradingView, indicating where this specific financial data point can be found on their platform for the company. It does not provide the actual value or detailed analysis but rather directs users to financial overview sections.
Enterprise value to EBIT forward of Avanos Medical, Inc. – SWB:8HH
This article provides the enterprise value to EBIT forward for Avanos Medical, Inc. (SWB:8HH) as listed on the Stuttgart Stock Exchange. It appears to be a financial data snippet from TradingView, offering current market information and various financial metrics for the company.
Avanos Medical Acquired by AIP and Taken Private
Avanos Medical has been acquired by affiliates of American Industrial Partners (AIP) in a going-private transaction valued at approximately $1.272 billion, with shareholders receiving $25.00 per share in cash. Following the acquisition on July 27, 2026, Avanos' common stock ceased trading on the NYSE and will be delisted, ending its public reporting obligations. AIP plans to leverage its operational expertise to accelerate Avanos' innovation and growth in the medical technology sector.
Price to sales forward of Avanos Medical, Inc. – SWB:8HH
This article from TradingView provides financial information for Avanos Medical, Inc. (SWB:8HH), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or an incomplete financial data page, as no specific values or analysis are present. It primarily consists of navigation and boilerplate information about TradingView's offerings.
Vanguard Capital Management (AVNS) discloses 2.34M-share, 5% holding in Avanos
Vanguard Capital Management has disclosed a beneficial ownership of 2,344,195 shares, representing a 5% stake in Avanos Medical Inc. This holding grants Vanguard sole voting power over 350,401 shares and sole dispositive power over all 2,344,195 shares. The shares are held by various Vanguard funds and managed accounts, benefiting from dividends and sale proceeds.
Price to earnings forward of Avanos Medical, Inc. – SWB:8HH
The article focuses on the "Price to earnings forward" metric for Avanos Medical, Inc. (SWB:8HH) on the Stuttgart Stock Exchange. It provides a financial overview and notes that the market is currently closed with no trades. The article is primarily a financial data page from TradingView, offering a snapshot of the company's financial status.
Price to earnings forward of Avanos Medical, Inc. – LSX:A2JNRG
This article provides access to the "Price to earnings forward" financial metric for Avanos Medical, Inc. (LSX:A2JNRG) on the TradingView platform. It highlights that no trades occurred for this stock, and the market is currently closed. Users can find detailed financial information, documents, community insights, and technical analysis related to Avanos Medical on the platform.
Avanos Medical Announced Transfer or Voluntary Withdrawal of Listing
Avanos Medical (AVNS) announced on July 27, 2026, its request to the NYSE for a trading suspension and the filing of Form 25 to delist and deregister its common stock following its merger. Trading of its shares was suspended on July 27, 2026. The company plans to file Form 15 to deregister its shares and suspend SEC reporting obligations upon the effectiveness of Form 25.
Avanos Medical Secures $775 Million Term Loans and $100 Million Revolver to Fund Take-Private
Avanos Medical has finalized new secured credit facilities totaling $775 million in term loans and a $100 million revolving credit facility, set to mature in 2033. These new facilities will support the company's take-private merger and ensure future liquidity, while simultaneously replacing its previous credit agreement with JPMorgan. The move aligns Avanos Medical's capital structure with its post-merger strategy.
Latham Advises on Financing for American Industrial Partners’ Completed US$1.272 Billion Acquisition of Avanos Medical, Inc.
Latham & Watkins LLP advised the financing sources for American Industrial Partners' (AIP) acquisition of Avanos Medical, Inc. for approximately US$1.272 billion. The transaction involved a large legal team from Latham, providing expertise across various areas including capital markets, banking, executive compensation, data transactions, healthcare, environmental, and tax matters. This marks a significant deal for AIP, an industrials investor, in expanding its portfolio.
Sterlington Advises Avanos Medical Management on $1.27B Acquisition
Sterlington law firm is advising the management team of Avanos Medical regarding its $1.27 billion acquisition by American Industrial Partners. The transaction highlights Sterlington's expertise in advising management teams in large take-private deals, particularly expanding its healthcare advisory practice. This engagement follows Sterlington's involvement in a quarter of U.S. take-private deals over $1 billion in the past year.
Avanos Medical (NYSE: AVNS) director cashed out in $25 per-share merger
Avanos Medical director Patrick J. O’Leary reported the disposition of 54,640 common shares and 12,003 restricted share units on July 27, 2026, as part of a merger. Each share and unit was converted into the right to receive $25.00 in cash, resulting in O'Leary holding no direct shares after the transaction. The merger, between Avanos Medical and A-AV Holdco I, Inc. and A-AV MergerSub, Inc., became effective on July 27, 2026.
Sterlington Advises Avanos Medical Management Team on $1.27 Billion Acquisition
Sterlington is advising the management team of Avanos Medical, Inc. on its acquisition by affiliates of investment funds advised by American Industrial Partners (AIP) for approximately $1.27 billion. This transaction expands Sterlington's portfolio of take-private advisory engagements and its health sector involvement. The Sterlington team was led by Executive Compensation partner Jeremy Goldtein and Corporate partners Christopher Harrison and Evan Coren.
Sterlington Advises Avanos Medical Management Team on $1.27 Billion Acquisition
Sterlington PLLC is advising the management team of Avanos Medical, Inc. on its acquisition by affiliates of American Industrial Partners (AIP) for approximately $1.27 billion. This engagement adds to Sterlington's growing portfolio of take-private advisory roles, particularly in the healthcare sector, and highlights their expertise in complex corporate transactions. The Sterlington team was led by partners Jeremy Goldstein, Christopher Harrison, and Evan Coren.
Avanos Medical, Inc. Revenue Breakdown – SWB:8HH
Avanos Medical, Inc. generated €597.01 million in revenue last year, with its Specialty Nutrition Systems - Enteral Feeding segment contributing the most at €267.94 million. The majority of this revenue, €463.09 million, originated from North America, though this was a decrease from the previous year's €526.46 million in the region. This financial breakdown offers insight into the company's key revenue drivers by segment and geographical region.
Avanos Medical (NYSE: AVNS) director cashed out in $25 merger
Avanos Medical director Julie Ann Shimer reported dispositions of 50,090 common shares and 12,003 restricted share units at $25.00 per share due to a merger effective July 27, 2026. These transactions resulted in her holding no remaining common stock or restricted share units in Avanos Medical. The filing indicates the transactions were a mechanical outcome of the merger agreement rather than discretionary trades.
Avanos Medical (NYSE: AVNS) CFO details $25 cash merger treatment of shares, RSUs and options
Avanos Medical CFO Scott Michael Galovan reported details on the company's merger, where each common share was converted into $25.00 cash. This transaction involved the exchange of 135,596 shares of common stock, including time-based restricted stock units, for cash. Additionally, 96,121 performance-based restricted stock units were settled at target performance, and various employee stock options were canceled for their in-the-money value.
Avanos Medical (AVNS) CEO equity awards converted to $25 cash in merger
Avanos Medical CEO David Pacitti's equity awards were converted to cash at $25.00 per share due to the merger effective July 27, 2026. This included the disposition of 322,194 common shares and the conversion of 444,730 performance-based RSUs and 239,354 stock options into cash, reflecting the terms of the merger agreement. Options with an exercise price exceeding the merger consideration were canceled without consideration.
Latham Advises on Financing for American Industrial Partners Completed Acquisition of Avanos Medical
Latham & Watkins LLP advised on the financing for American Industrial Partners' (AIP) acquisition of Avanos Medical, Inc., a deal valued at approximately US$1.272 billion. AIP, an industrials investor, announced the closing of this significant acquisition. The Latham team involved multiple partners and associates specializing in various legal areas, including capital markets, banking, and healthcare.
Avanos Medical Will Become Private With AIP Deal Complete
American Industrial Partners (AIP) has completed its acquisition of Avanos Medical (NYSE: AVNS) for approximately $1.272 billion. Avanos stockholders will receive $25.00 in cash per share, and the company's common stock will cease trading on the New York Stock Exchange, making Avanos privately held. This partnership aims to support Avanos's growth and innovation in the medical technology sector, leveraging AIP's operational expertise.
Press Release: American Industrial Partners Completes Acquisition of Avanos Medical, Inc.
This press release announces that American Industrial Partners (AIP) has successfully completed its acquisition of Avanos Medical, Inc. The acquisition marks a significant change for Avanos Medical, transitioning it from a publicly traded company to a privately held entity under AIP's ownership. The move aims to enhance Avanos's operational capabilities and market position with the strategic support of its new owner.
American Industrial Partners Completes Acquisition of Avanos Medical, Inc.
American Industrial Partners (AIP) has finalized its acquisition of Avanos Medical, Inc. in a transaction valued at approximately $1.272 billion, with Avanos stockholders receiving $25.00 per share in cash. Following the acquisition, Avanos will become a private company, and its common stock will cease trading on the New York Stock Exchange. Both AIP and Avanos leadership expressed optimism about leveraging AIP's operational expertise for continued growth and innovation in the medical technology sector.
Avanos Medical (AVNS) moves to withdraw NYSE listing of its common stock
Avanos Medical, Inc. (AVNS) has filed a Form 25-NSE with the SEC to voluntarily delist its common stock from the New York Stock Exchange. This action is being taken under Section 12(b) of the Securities Exchange Act of 1934 and 17 CFR 240.12d2-2(c), which governs voluntary withdrawals. The delisting process signifies a formal removal from NYSE trading and registration.
Avanos Medical, Inc.(NYSE:AVNS) dropped from S&P Healthcare Equipment Select Industry Index
Avanos Medical, Inc. (AVNS) has been removed from the S&P Healthcare Equipment Select Industry Index. This follows several other recent index removals, including various Russell indices. Avanos Medical is a medical technology company focused on delivering medical device solutions for nutrition, pain management, and recovery.
Avanos Medical, Inc. Revenue Breakdown – NYSE:AVNS
Avanos Medical, Inc. (NYSE: AVNS) generated a total revenue of $701.20 million USD last year. Its top-performing segment was Specialty Nutrition Systems - Enteral Feeding, contributing $314.70 million USD, while North America was the largest regional contributor with $543.90 million USD.
Avanos Medical, Inc. (AVNS) Stock Forecasts
This article provides a stock forecast for Avanos Medical, Inc. (AVNS), a U.S.-based medical device company. An Argus research report, dated July 1, 2026, rates the company and includes a current price of $24.99, urging users to upgrade for full access to the report and other premium features.
Avanos Medical, Inc. (AVNS) Stock Forecasts
This article provides a stock forecast summary for Avanos Medical Inc (AVNS), a U.S.-based medical device company. It highlights the current price of $24.99 and mentions the availability of a full report from Argus, dated July 8, 2026, for premium users. The summary also lists related analyst reports for other companies.
AVNS|Avanos Medical Inc|Price:24.990|Chg%:+0.010
Avanos Medical Inc (AVNS) is trading at $24.990 with a slight increase of +0.04%. The company's fundamentals are robust with high growth potential, and its valuation is considered fairly valued within the Healthcare Equipment & Supplies industry. Analysts currently rate the stock as "Hold" with a target price of $14.00, suggesting a potential upside despite its current trading levels.
Avanos Medical (AVNS) Rebounds Sharply, Is The Stock Above Fair Value?
Avanos Medical (AVNS) has seen a sharp rebound in its share price, with a 123.43% year-to-date return, despite reporting a net loss of $74.4 million on revenues of $715.9 million. The company currently trades at a price-to-sales (P/S) ratio of 1.6x, considered overvalued compared to its estimated fair P/S of 1.2x, although it appears undervalued relative to the broader US Medical Equipment industry average. Investors are advised to review the company's financials and potential risks due to its mixed performance and current valuation.
Avanos Medical Stockholders Approve Acquisition By American Industrial Partners
Avanos Medical stockholders have officially approved the acquisition of the company by American Industrial Partners. This news was reported by Reuters and is available through Refinitiv. Interested parties can access further details via a free trial.
Avanos Medical, Inc. Stockholders Approve Acquisition by American Industrial Partners
Avanos Medical, Inc. stockholders have approved the acquisition by American Industrial Partners (AIP) with approximately 99.75% of shares voted in favor. The cash transaction will provide Avanos stockholders with $25.00 per share, and all required regulatory approvals have been received. The acquisition is expected to close no later than July 27, 2026, marking a significant step for Avanos to enhance flexibility and resources in addressing healthcare needs.
Avanos cash deal expected to close by July 27 after ~99.75% approval
Avanos Medical stockholders have approved the acquisition by American Industrial Partners (AIP) for $25.00 cash per share, with approximately 99.75% of votes cast in favor. All necessary regulatory approvals have been secured, and the transaction is anticipated to close no later than July 27, 2026, subject to customary closing conditions. This partnership is expected to provide Avanos with enhanced flexibility and resources to address healthcare needs.
Avanos stock trades steadily as medical devices business focuses on margin and cash flow
Avanos Medical Inc. (AVNS) is demonstrating a steady performance in its medical devices sector, emphasizing improved operating margins and stronger free cash flow. Despite a slight revenue decline due to divestments and currency effects, the company's strategic focus on profitability, efficiency, and higher-margin product lines like chronic pain solutions has led to a significant increase in free cash flow and a manageable net debt position. Investors are observing the company's efforts in portfolio streamlining and efficiency programs as key drivers for value, supported by continuous investment in R&D.
(AVNS) Volatility Zones as Tactical Triggers
This article analyzes Avanos Medical Inc. (NASDAQ: AVNS), identifying a neutral near- and mid-term outlook that could moderate a long-term positive bias. It highlights a significant short setup with an exceptional 42.0:1
Avanos Medical (AVNS) Proxy filing Summary
Avanos Medical (AVNS) has filed a proxy statement detailing a merger agreement from April 13, 2026, which will make the company a wholly-owned subsidiary of a parent entity. A special shareholder meeting is set for July 22, 2026, to vote on the merger, advisory compensation, and adjournment proposals, all of which the board unanimously recommends. Supplemental proxy disclosures were issued to address shareholder lawsuits alleging disclosure deficiencies, though the company denies wrongdoing.
Avanos to supplement proxy after shareholder suits; J.P. Morgan valuation range cited
Avanos will voluntarily supplement its definitive proxy statement due to shareholder lawsuits alleging disclosure deficiencies related to its pending $25.00-per-share merger. The company denies the allegations, stating the supplement aims to avoid litigation delays and costs, without altering merger terms or the board's recommendation. J.P. Morgan's analyses showed implied per-share ranges of $12.75–$23.50 based on public comps and $9.75–$21.75 from selected transactions, which were compared to the $25.00 merger consideration.
Avanos Medical (AVNS) Q4 2024 earnings summary
Avanos Medical (AVNS) reported strong Q4 and full-year 2024 performance, driven by Enteral Feeding growth and the completion of its respiratory health business divestiture. Despite a net loss due to a non-cash impairment charge, the company achieved significant increases in adjusted diluted EPS and free cash flow. For 2025, Avanos expects net sales between $665M-$685M and adjusted diluted EPS of $1.05-$1.25, while focusing on portfolio optimization and cost management.
Price to earnings forward of Avanos Medical, Inc. – MUN:8HH
This article displays the "Price to earnings forward" metric for Avanos Medical, Inc. (MUN:8HH) on the TradingView platform. The content primarily shows navigation and interface elements of the TradingView site, with the specific financial data point itself being "Period Value Change Change % Made by humans." It features no detailed financial analysis or additional context.
Latham Advises on Financing for American Industrial Partners’ US$1.272 Billion Acquisition of Avanos Medical, Inc.
Latham & Watkins LLP represented the financing sources for American Industrial Partners' (AIP) acquisition of Avanos Medical, Inc., a medical technology company. AIP acquired Avanos in an all-cash transaction valued at approximately US$1.272 billion. The Latham team involved partners from various practices including Capital Markets, Executive Compensation, Data and Technology Transactions, Healthcare, Environment, and Tax.
Has Avanos Medical (AVNS) Run Ahead Of Fundamentals On Its Russell Index Removal?
Avanos Medical (AVNS) was recently removed from the Russell 2000 Defensive and Value-Defensive Indexes, which can impact institutional trading. Despite this, AVNS has seen significant recent share price gains of 79.02% over 90 days and 122.90% year-to-date. The article questions if its current price-to-sales ratio of 1.6x is justified, noting it's above its estimated fair P/S of 1.2x but below industry and peer averages, even while the company remains unprofitable.
Avanos Medical (AVNS) Q4 2024 earnings summary
Avanos Medical (AVNS) reported strong Q4 and full-year 2024 performance, driven by growth in Enteral Feeding and the divestiture of its respiratory health business. Despite a net loss due to a non-cash impairment charge, the company achieved significant increases in adjusted diluted EPS and free cash flow. For 2025, Avanos expects net sales between $665M-$685M and adjusted diluted EPS in the range of $1.05-$1.25, with anticipated margin expansion in 2026.
Has Avanos Medical (AVNS) Run Ahead Of Fundamentals On Its Russell Index Removal?
Avanos Medical (AVNS) was recently removed from Russell 2000 indices, yet its share price has seen significant growth, up 79.02% in 90 days and 122.90% year-to-date. Despite this surge, its P/S ratio of 1.6x is above its estimated fair value of 1.2x but undervalued compared to the broader US Medical Equipment industry average. The company has faced losses over the past five years and has a negative return on equity, suggesting its recent price performance might outpace fundamental improvements.
Enterprise value to EBIT forward of Avanos Medical, Inc. – LS:A2JNRG
This article provides financial data for Avanos Medical, Inc. (LS:A2JNRG) focusing on its Enterprise Value to EBIT forward ratio. It highlights the availability of financial figures and market data for the company through TradingView, noting that the market is currently closed.
Avanos Medical (AVNS) Q1 2026 earnings summary
Avanos Medical announced its Q1 2026 earnings, reporting net sales of $182.2 million, an 8.8% increase year-over-year, driven by strong growth in Specialty Nutrition Systems. The company also announced a definitive agreement to be acquired by affiliates of American Industrial Partners for $1.272 billion, with shareholders receiving $25.00 per share in cash. This acquisition will result in Avanos Medical becoming a privately held company.
Enterprise value to revenue forward of Avanos Medical, Inc. – LS:A2JNRG
This article focuses on the enterprise value to revenue forward for Avanos Medical, Inc. (LS:A2JNRG). It appears to be a financial data point from TradingView, indicating a key valuation metric for the company. The content primarily highlights this specific financial metric without providing further analysis or details.
Avanos stock stays tied to medical devices.
Avanos Medical Inc (ISIN US05350V1061) is a Nasdaq-listed medical device company specializing in chronic care, pain management, and digestive health products. The company's business model relies on its portfolio of infection prevention, chronic care, and interventional products, which are used in hospital and home-care settings. The article emphasizes the importance of the company's operating mix and product categories, such as enteral feeding, for its growth in the healthcare market.
Avanos, American Industrial Get Regulatory Approval for Merger
Avanos and American Industrial have received regulatory approval for their merger. This development marks a significant step forward for the two companies as they proceed with their integration plans.
